Onchocerca volvulus: The Road from Basic Biology to a Vaccine.

Authors

Sara Lustigman, New York Blood Center
Benjamin L. Makepeace, University of Liverpool
Thomas R. Klei, Louisiana State University
Simon A. Babayan, University of Glasgow and Moredun Research Institute
Peter Hotez, Baylor College of Medicine
David Abraham, Thomas Jefferson UniversityFollow
Maria Elena Bottazzi, Baylor College of Medicine

Document Type

Article

Publication Date

1-2018

Comments

This article is the authors' final version prior to publication in Trends in Parasitology, Volume 34, Issue 1, January 2018, Pages 64-79.

The published version is available at https://doi.org/10.1016/j.pt.2017.08.011. Copyright © Lustigman et al.

Abstract

Human onchocerciasis - commonly known as river blindness - is one of the most devastating yet neglected tropical diseases, leaving many millions in sub-Saharan Africa blind and/or with chronic disabilities. Attempts to eliminate onchocerciasis, primarily through the mass drug administration of ivermectin, remains challenging and has been heightened by the recent news that drug-resistant parasites are developing in some populations after years of drug treatment. Needed, and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and therapeutic vaccines. This review summarizes the progress made to advance the onchocerciasis vaccine from the research laboratory into the clinic.

Recommended Citation

Lustigman, Sara; Makepeace, Benjamin L.; Klei, Thomas R.; Babayan, Simon A.; Hotez, Peter; Abraham, David; and Bottazzi, Maria Elena, "Onchocerca volvulus: The Road from Basic Biology to a Vaccine." (2018). Department of Microbiology and Immunology Faculty Papers. Paper 143.
https://jdc.jefferson.edu/mifp/143

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

28958602

Language

English